Hypercoagulability and Mortality of Patients with Stroke and Active Cancer: The OASIS-CANCER Study
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Background and Purpose Patients with active cancer are at an increased risk for stroke. Hypercoagulability plays an important role in cancer-related stroke. We aimed to test whether 1) hypercoagulability is a predictor of survival, and 2) correction of the hypercoagulable state leads to better survival in patients with stroke and active cancer. Methods We recruited consecutive patients with acute ischemic stroke and active systemic cancer between January 2006 and July 2015. Hypercoagulability was assessed using plasma D-dimer levels before and after 7 days of anticoagulation treatment. The study outcomes included overall and 1-year survival. Plasma D-dimer levels before and after treatment were tested in univariate and multivariate Cox regression models. We controlled for systemic metastasis, stroke mechanism, age, stroke severity, primary cancer type, histology, and atrial fibrillation using the forward stepwise method. Results A total of 268 patients were included in the analysis. Patients with high (3rd–4th quartiles) pre-treatment plasma D-dimer levels showed decreased overall and 1-year survival (adjusted HR, 2.19 [95% CI, 1.46–3.31] and 2.70 [1.68–4.35], respectively). After anticoagulation treatment, post-treatment D-dimer level was significantly reduced and independently associated with poor 1-year survival (adjusted HR, 1.03 [95% CI, 1.01–1.05] per 1 μg/mL increase, P=0.015). The successful correction of hypercoagulability was a protective factor for 1-year survival (adjusted HR 0.26 [CI 0.10–0.68], P=0.006). Conclusions Hypercoagulability is associated with poor survival after stroke in patients with active cancer. Effective correction of hypercoagulability may play a protective role for survival in these patients
Abstract
Background and Purpose Patients with active cancer are at an increased risk for stroke. Hypercoagulability plays an important role in cancer-related stroke. We aimed to test whether 1) hypercoagulability is a predictor of survival, and 2) correction of the hypercoagulable state leads to better survival in patients with stroke and active cancer. Methods We recruited consecutive patients with acute ischemic stroke and active systemic cancer between January 2006 and July 2015. Hypercoagulability was assessed using plasma D-dimer levels before and after 7 days of anticoagulation treatment. The study outcomes included overall and 1-year survival. Plasma D-dimer levels before and after treatment were tested in univariate and multivariate Cox regression models. We controlled for systemic metastasis, stroke mechanism, age, stroke severity, primary cancer type, histology, and atrial fibrillation using the forward stepwise method. Results A total of 268 patients were included in the analysis. Patients with high (3rd–4th quartiles) pre-treatment plasma D-dimer levels showed decreased overall and 1-year survival (adjusted HR, 2.19 [95% CI, 1.46–3.31] and 2.70 [1.68–4.35], respectively). After anticoagulation treatment, post-treatment D-dimer level was significantly reduced and independently associated with poor 1-year survival (adjusted HR, 1.03 [95% CI, 1.01–1.05] per 1 μg/mL increase, P=0.015). The successful correction of hypercoagulability was a protective factor for 1-year survival (adjusted HR 0.26 [CI 0.10–0.68], P=0.006). Conclusions Hypercoagulability is associated with poor survival after stroke in patients with active cancer. Effective correction of hypercoagulability may play a protective role for survival in these patients
참고문헌 (37)
- Cestari DM, "Stroke in patients with cancer: incidence and etiology", Neurology, 62, pp.2025~2030 (2004)
- Navi BB, "Association between incident cancer and subsequent stroke", Ann Neurol, 77, pp.291~300 (2015)
- Kim SJ, "Clues to occult cancer in patients with ischemic stroke", PLoS ONE, 7, pp.e44959~ (2012)
- Kim SG, "Ischemic stroke in cancer patients with and without conventional mechanisms: a multicenter study in Korea", Stroke, 41, pp.798~801 (2010)
- 방오영, "Ischemic Stroke and Cancer: Stroke Severely Impacts Cancer Patients, While Cancer Increases the Number of Strokes", Journal of Clinical Neurology, 7(2), pp.53~59 (2011), 대한신경과학회
- Schwarzbach CJ, "Stroke and cancer: the importance of cancer-associated hypercoagulation as a possible stroke etiology", Stroke, 43, pp.3029~3034 (2012)
- Seok JM, "Coagulopathy and embolic signal in cancer patients with ischemic stroke", Ann Neurol, 68, pp.213~219 (2010)
- Smith EE, "Risk score for in-hospital ischemic stroke mortality derived and validated within the Get With the Guidelines-Stroke Program", Circulation, 122, pp.1496~1504 (2010)
- Navi BB, "Cryptogenic subtype predicts reduced survival among cancer patients with ischemic stroke", Stroke, 45, pp.2292~2297 (2014)
- Buccheri G, "Haemostatic abnormalities in lung cancer: prognostic implications", Eur J Cancer, 33, pp.50~55 (1997)
- Lee AY, "Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer", N Engl J Med, 349, pp.146~153 (2003)
- Vedovati MC, "Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis", Chest, 147, pp.475~483 (2015)
- Agnelli G, "Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study", Lancet Oncol, 10, pp.943~949 (2009)
- Akl EA, "Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer", Cochrane Database Syst Rev, 7, pp.CD006650~ (2014)
- Streiff MB, "The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients", Thromb Res, 125(Suppl 2), pp.S128~S133 (2010)
- Toh CH, "The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview", J Thromb Haemost, 5, pp.604~606 (2007)
- Ebrahim S, "Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort study", BMJ, 333, pp.22~ (2006)
- Kuderer NM, "Impact of venous thromboembolism and anticoagulation on cancer and cancer survival", J Clin Oncol, 27, pp.4902~4911 (2009)
- Nierodzik M, "Hypercoagulability preceding cancer. Does hypercoagulability awaken dormant tumor cells in the host?", J Thromb Haemost, 3, pp.577~580 (2005)
- Sorensen HT, "Prognosis of cancers associated with venous thromboembolism", N Engl J Med, 343, pp.1846~1850 (2000)
- Chew HK, "Incidence of venous thromboembolism and its effect on survival among patients with common cancers", Arch Intern Med, 166, pp.458~464 (2006)
- Ageno W, "Plasma measurement of D-dimer levels for the early diagnosis of ischemic stroke subtypes", Arch Intern Med, 162, pp.2589~2593 (2002)
- 박영우, "Correlation between Serum D-Dimer Level and Volume in Acute Ischemic Stroke", 대한신경외과학회지, 50(2), pp.89~94 (2011), 대한신경외과학회
- 김광수, "Risk Factors and Biomarkers of Ischemic Stroke in Cancer Patients", 대한뇌졸중학회지, 16(2), pp.91~96 (2014), 대한뇌졸중학회[DOI]
- Jang H, "Comparison of Enoxaparin and Warfarin for Secondary Prevention of Cancer-Associated Stroke", J Oncol, 2015, pp.502089~ (2015)
- Levi M, "Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology", Br J Haematol, 145, pp.24~33 (2009)
- Ratajczak J, "Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication", Leukemia, 20, pp.1487~1495 (2006)
- Bang OY, "Cancer cell-derived extracellular vesicles are associated with coagulopathy causing ischemic stroke via tissue factor-independent way: the OASIS-CANCER study", PLoS ONE, 11, pp.e0159170~ (2016)
- Kuderer NM, "A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications", Cancer, 110, pp.1149~1161 (2007)
- Carter AM, "Predictive variables for mortality after acute ischemic stroke", Stroke, 38, pp.1873~1880 (2007)
- Rabinstein A, "Prediction of outcome after ischemic stroke: the value of clinical scores", Neurology, 80, pp.15~16 (2013)
- Bruix J, "Management of hepatocellular carcinoma: an update", Hepatology, 53, pp.1020~1022 (2011)
- Vincent A, "Pancreatic cancer", Lancet, 378, pp.607~620 (2011)
- Razumilava N, "Cholangiocarcinoma", Lancet, 383, pp.2168~2179 (2014)
- Navi BB, "Recurrent thromboembolic events after ischemic stroke in patients with cancer", Neurology, 83, pp.26~33 (2014)
- Falanga A, "Mechanisms of hypercoagulation in malignancy and during chemotherapy", Haemostasis, 28(Suppl 3), pp.50~60 (1998)
- Iguchi Y, "Ischaemic stroke with malignancy may often be caused by paradoxical embolism", J Neurol Neurosurg Psychiatry, 77, pp.1336~1339 (2006)